Article Abstract

Is stronger better in curing hepatitis C virus infection?

Authors: Stanislas Pol

Abstract

Thanks to a better understanding of the hepatitis C virus (HCV) life-cycle, HCV direct-acting antiviral agents (DAAs) targeting the viral proteins implicated in the virus replication have been developed: they inhibit specifically the NS3/4A protease, the NS5B polymerase and the multifunctional NS5A replication complex (1). DAAs have revolutionized the treatment of HCV infection over the last 5 years. Oral interferon-free combinations of at least two DAAs showed high antiviral efficacy, easy dosing, fair tolerance, and manageable drug-drug interactions, whatever the combination for treatment duration of 8, 12 or 24 weeks according to the patients profile.